Get 40% Off
🤯 Perficient is up a mind-blowing 53%. Our ProPicks AI saw the buying opportunity in March.Read full update

U.S. to invest $3 billion in COVID-19 vaccine supply chain -White House official

Published 09/02/2021, 03:32 PM
Updated 09/02/2021, 04:31 PM
© Reuters. FILE PHOTO: Vials labelled "Moderna, Johnson & Johnson, Pfizer-BioNTech coronavirus disease (COVID-19) vaccine" are seen in this illustration picture taken May 2, 2021. REUTERS/Dado Ruvic

By Carl O'Donnell and Lisa Lambert

(Reuters) -The U.S. plans to invest $3 billion in the vaccine supply chain as it continues to work to position itself as a leading supplier of vaccines for the world, a top U.S. health official said on Thursday.

The funding, which will begin to be distributed in the coming weeks, will focus on manufacturers of the inputs used in COVID-19 vaccine production as well as facilities that fill and package vaccine vials, White House COVID adviser Jeffrey Zients said during a news conference.

"The investments we are making, the $3 billion, are in U.S. companies that will expand their capacity for critical supplies," Zients said.

He added that areas of focus will include lipids, bioreactor bags, tubing, needles, syringes, and personal protective equipment. The White House has not yet selected specific companies to receive the funds.

U.S. demand for COVID-19 vaccines remains high as the White House prepares to begin offering a third booster shot to Americans later this month, pending a regulator greenlight. The United States also plans to give hundreds of millions of shots to other countries during the remainder of the year.

Top U.S. infectious disease expert Anthony Fauci added that he would not be surprised if a third dose became standard for COVID-19 vaccines that originally were expected to require two shots.

U.S. cases of COVID-19 have surged to a seven-day average of more than 150,000 per day, up from less than 10,000 in June, according to federal data, as the contagious new Delta variant continues to circulate.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

The daily average of COVID-19 deaths has risen this week to more than 950 from around 900 last week, U.S. Centers for Disease Control and Prevention Director Rochelle Walensky said.

Fauci downplayed concerns about a new COVID-19 variant known as Mu, or B.1.621, that some scientists are concerned could be resistant to vaccines.

"Even when you have variants that do diminish somewhat the efficacy of vaccines, the vaccines still are quite effective against variants of that type," Fauci said.

Latest comments

lol they need more fundings
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.